LRRC1 and lung carcinoma: Tumor proliferation, invasion, and metastasis can be inhibited by knocking down LRRC1 to increase the efficacy of ensartinib in advanced lung cancer, as shown in non-small-cell lung cancer studies (Qiu et al., 2021).